Dimitar Divchev

Dr. Dimitar Divchev

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
HSHarald Schuett
Harald Schuett
RORené Oestreich
René Oestreich
GWGeorg H. Waetzig
Georg H. Waetzig
WAWijtske Annema
Wijtske Annema
MLMaren Luchtefeld
Maren Luchtefeld
Karsten GroteKarsten Grote
Karsten Grote
Objective—: Transsignaling of interleukin (IL)-6 is a central pathway in the pathogenesis of disorders associated with chronic inflammation, such as Crohn disease, rheumatoid arthritis, and inflammatory colon cancer. Notably, IL-6 also represents an independent risk factor for coronary artery disease (CAD) in humans and is crucially involved in vascular inflammatory processes. Methods and Results—: In the present study, we showed that treatment with a fusion protein of the natural IL-6 transsignaling inhibitor soluble glycoprotein 130 (sgp130) and IgG1-Fc (sgp130Fc) dramatically reduced atherosclerosis in hypercholesterolemic Ldlr −/− mice without affecting weight gain and serum lipid levels. Moreover, sgp130Fc treatment even led to a significant regression of advanced atherosclerosis. Mechanistically, endothelial activation and intimal smooth muscle cell infiltration were decreased in sgp130Fc-treated mice, resulting in a marked reduction of monocyte recruitment and subsequent atherosclerotic plaque progression. Of note, patients with CAD exhibited significantly lower plasma levels of endogenous sgp130, suggesting that a compromised counterbalancing of IL-6 transsignaling may contribute to atherogenesis in humans. Conclusion—: These data clarify, for the first time, the critical involvement of, in particular, the transsignaling of IL-6 in CAD and warrant further investigation of sgp130Fc as a novel therapeutic for the treatment of CAD and related diseases.

7 February 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Joerg EberhardJoerg Eberhard
Joerg Eberhard
Karsten GroteKarsten Grote
Karsten Grote
MLMaren Luchtefeld
Maren Luchtefeld
WHWieland Heuer
Wieland Heuer
HSHarald Schuett
Harald Schuett
MSMeike Stiesch
Meike Stiesch
We here investigated whether experimental gingivitis enhances systemic markers of inflammation which are also known as surrogate markers of atherosclerotic plaque development. Gingivitis is a low-level oral infection induced by bacterial deposits with a high prevalence within Western populations. A potential link between the more severe oral disease periodontitis and cardiovascular disease has already been shown. 37 non-smoking young volunteers with no inflammatory disease or any cardiovascular risk factors participated in this single-subject interventional study with an intra-individual control. Intentionally experimental oral inflammation was induced by the interruption of oral hygiene for 21 days, followed by a 21-days resolving phase after reinitiation of oral hygiene. Primary outcome measures at baseline, day 21 and 42 were concentrations of hsCRP, IL-6, and MCP-1, as well as adhesion capacity and oxLDL uptake of isolated blood monocytes. The partial cessation of oral hygiene procedures was followed by the significant increase of gingival bleeding (34.0%, P<0.0001). This local inflammation was associated with a systemic increase in hsCRP (0.24 mg/L, P = 0.038), IL-6 (12.52 ng/L, P = 0.0002) and MCP-1 (9.10 ng/l, P = 0.124) in peripheral blood samples between baseline and day 21, which decreased at day 42. Monocytes showed an enhanced adherence to endothelial cells and increased foam cell formation after oxLDL uptake (P<0.050) at day 21 of gingivitis. Bacterial-induced gingival low-level inflammation induced a systemic increase in inflammatory markers. Dental hygiene almost completely reversed this experimental inflammatory process, suggesting that appropriate dental prophylaxis may also limit systemic markers of inflammation in subjects with natural gingivitis. International Clinical Trials Register Platform of the World Health Organization, registry number: DRKS00003366, URL: http://apps.who.int/trialsearch/Default.aspx

4 October 2012 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
IAIbrahim Akin
Ibrahim Akin
SKStephan Kische
Stephan Kische
LPLylia Paranskaya
Lylia Paranskaya
HSHenrik Schneider
Henrik Schneider
TRTim C Rehders
Tim C Rehders
HIHüseyin Ince
Hüseyin Ince
Transcatheter aortic valve implantation (TAVI) has been established as a treatment option for inoperable patients with symptomatic aortic valve stenosis. However, patients suffer frequently from conduction disturbances after TAVI. Baseline, procedural as well as surface and intracardiac ECG parameters were evaluated for patients treated with TAVI and a comparison between patients requiring pacemaker with those not suffering from relevant conduction disorders were done. TAVI was successfully in all patients (n=45). Baseline surface and intracardiac ECG recording revealed longer PQ (197.1±51.2 msec versus 154.1±32.1 msec; p<0.001), longer AH (153.6±43.4 msec versus 116.1±31.2 msec; p<0.001) and HV interval (81.7±17.8 msec versus 56.8±8.5 msec; p<0.001) in patients with need for a pacemaker (n=23) versus control group (n=22); furthermore, 7-day follow-up analysis showed a higher prevalence of new left bundle branch block (LBBB) (87.0% versus 31.9%; p120 msec and a PQ interval >200 msec immediately (within 60 minutes) after implantation of the aortic valve were predictors for high-grade (type II second-degree and third-degree) AV block. Other clinical parameters as well as baseline electrocardiographic parameters had no impact on critical conduction delay. Cardiac conduction disturbances are common after TAVI. The need for pacing after TAVI is predictable by surface ECG evaluation immediately (within 60 minutes) after the procedure.

4 August 2014 in Heart
Verified
Journal Article
Closed access
CNChristoph A Nienaber
Christoph A Nienaber
DDDimitar Divchev
Dimitar Divchev
HPHolger Palisch
Holger Palisch
RCRachel E Clough
Rachel E Clough
BRBarbara Richartz
Barbara Richartz
The management of type B aortic dissection is undergoing profound changes with timely TEVAR accepted as first-line strategy in the setting of complicated dissection; with recent technological advances and in experienced hands this intervention is considered safe and life-saving. With the ability to remodel the dissected aorta as a result of scaffolding even pre-emptive endovascular treatment is being considered and supported by long-term stability and often prevention of aneurysmal expansion. This insight and a growing number of silent risk conditions (resistant hypertension, partial false lumen thrombosis) may lower the threshold for TEVAR in asymptomatic patients in the subacute phase. In the chronic phase of a type B dissection patients are usually free of symptoms, however, with the expanding false lumen at risk of rupture. Advanced TEVAR options (including branches and fenestrations) are likely to be used more often than open surgical replacement of such aneurysmatic segment of the dissected aorta in that chronic phase. All dissection patients should be offered lifelong surveillance.

1 September 2012 in EuroIntervention
Verified
Journal Article
Closed access
LPLiliya Paranskaya
Liliya Paranskaya
GDGiuseppe D’aNcona
Giuseppe D’aNcona
IBIlkay Bozdag-Turan
Ilkay Bozdag-Turan
IAIbrahim Akin
Ibrahim Akin
SKStephan Kische
Stephan Kische
HIHüseyin Ince
Hüseyin Ince
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

1 January 2007 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
DDDimitar Divchev
Dimitar Divchev
ASArnd Schaefer
Arnd Schaefer
MFMartin Fuchs
Martin Fuchs
TBThomas Breymann
Thomas Breymann
HDHelmut Drexler
Helmut Drexler
GMGerd Peter Meyer
Gerd Peter Meyer
We report on a case of a mobile left atrial thrombus formation on an atrial septal defect occluder system (28mm StarFLEX ® -Occluder) despite 6 mont